SCHEMBL365167

SCHEMBL365167

O=C(O)c1ccc(F)cc1CO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.50
DCLRE1B Q9H816 2/20 0.49
CES2 O00748 2/20 0.45
CES1 P23141 2/20 0.45
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
TTR P02766 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.44
HMGB1 P09429 2/20 0.44
HPGD P15428 2/20 0.44
CXCL12 P48061 2/20 0.44
HSD17B10 Q99714 2/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
DHFR P00374 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
ALB P02768 1/20 0.44
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16429122 0.86 KEAP1 (0.52) KEAP1DCLRE1BCES2CES1KDM4E
SCHEMBL26866 0.85 KEAP1 (0.47) KEAP1DCLRE1BCES2CES1KDM4E
SCHEMBL65008 0.84 KEAP1 (0.50) KEAP1DCLRE1BCES2CES1KDM4E
SCHEMBL4146826 0.84 KEAP1 (0.55) KEAP1DCLRE1BCES2CES1KDM4E
Hydrochloric Acid SCHEMBL29118312 0.83 KEAP1 (0.46) KEAP1DCLRE1BCES2CES1KDM4E
SCHEMBL22341265 0.82 KEAP1 (0.48) KEAP1DCLRE1BCES2CES1KDM4E
SCHEMBL2923481 0.82 TSHR (0.50) KEAP1DCLRE1BCES2CES1KDM4E
SCHEMBL21815740 0.82 KEAP1 (0.48) KEAP1DCLRE1BCES2CES1KDM4E
SCHEMBL13806629 0.82 KEAP1 (0.48) KEAP1DCLRE1BCES2CES1KDM4E
Hydrochloric Acid SCHEMBL29118324 0.82 KEAP1 (0.48) KEAP1DCLRE1BCES2CES1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
EP-2593427-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007883-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2012-01-19 WO disclosed
WO-2012007883-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A KEAP1 1810/4885DCLRE1B 4876/4885CES2 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.